Title |
Lacosamide for neuropathic pain and fibromyalgia in adults
|
---|---|
Published in |
Cochrane database of systematic reviews, February 2012
|
DOI | 10.1002/14651858.cd009318.pub2 |
Pubmed ID | |
Authors |
Leslie Hearn, Sheena Derry, R Andrew Moore |
Abstract |
Antiepileptic drugs have been used in pain management since the 1960s; some seem to be especially useful for neuropathic pain. Lacosamide is an antiepileptic drug that has recently been investigated for neuropathic pain relief, although it failed to get approval for painful diabetic peripheral neuropathy from either the Food and Drug Administration or the European Medicines Agency. |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 3 | 33% |
United States | 3 | 33% |
Switzerland | 1 | 11% |
Unknown | 2 | 22% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 7 | 78% |
Science communicators (journalists, bloggers, editors) | 2 | 22% |
Mendeley readers
The data shown below were compiled from readership statistics for 208 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 2 | <1% |
United Kingdom | 1 | <1% |
France | 1 | <1% |
Unknown | 204 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 38 | 18% |
Researcher | 22 | 11% |
Student > Bachelor | 18 | 9% |
Other | 14 | 7% |
Student > Doctoral Student | 14 | 7% |
Other | 41 | 20% |
Unknown | 61 | 29% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 70 | 34% |
Nursing and Health Professions | 20 | 10% |
Pharmacology, Toxicology and Pharmaceutical Science | 12 | 6% |
Psychology | 9 | 4% |
Agricultural and Biological Sciences | 6 | 3% |
Other | 26 | 13% |
Unknown | 65 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 August 2023.
All research outputs
#2,497,630
of 24,272,486 outputs
Outputs from Cochrane database of systematic reviews
#5,193
of 12,876 outputs
Outputs of similar age
#20,122
of 258,434 outputs
Outputs of similar age from Cochrane database of systematic reviews
#64
of 216 outputs
Altmetric has tracked 24,272,486 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,876 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 33.9. This one has gotten more attention than average, scoring higher than 59% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 258,434 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 216 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.